Purpose Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of immunosuppressive cells that are upregulated in cancer. Little is known about the prevalence and importance of MDSC in pancreas adenocarcinoma (PA). Experimental design Peripheral blood, bone marrow, and tumor samples were collected from pancreatic cancer patients, analyzed for MDSC (CD15 + CD11b + ) by Xow cytometry and compared to cancer-free controls. The suppressive capacity of MDSC (CD11b + Gr-1 + ) and the eVectiveness of MDSC depletion were assessed in C57BL/6 mice inoculated with Pan02, a murine PA, and treated with placebo or zoledronic acid, a potent aminobisphosphonate previously shown to target MDSC. The tumor microenvironment was analyzed for MDSC (Gr1 
Introduction
Tumor-induced alterations in bone marrow myelopoiesis are driven by growth factors and cytokines secreted by the primary tumor resulting in myeloid-derived suppressor cell (MDSC) expansion and mobilization [1] [2] [3] . MDSC are a heterogeneous population of immature and undiVerentiated myeloid cells found in increased numbers in numerous cancers including breast, prostate, renal cell, melanoma, and lung [4] [5] [6] [7] [8] [9] . The prevalence of these cells in cancer patients correlates with disease stage, and normalization in MDSC numbers occurs after successful treatment [10] . Once mobilized to the tumor stroma, MDSC promote primary tumor growth and invasion through a variety of mechanisms: arginase production, iNOS and ROS upregulation, L-selectin down regulation, cysteine depletion, promotion of neoan-giogenesis, and regulatory T-cell recruitment [6, 7, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . MDSC also promote tumor-induced immunosuppression and host immune evasion by inhibiting lymphocyte activation and antigen recognition [27, 28] .
The identiWcation and classiWcation of MDSC in human cancers remain a diYcult problem due to the considerable heterogeneity of this group of myelomonocytic cells. Although MDSC in murine models of cancers reliably express Gr-1 + CD11b + , there is no direct analogs cell surface marker for Gr-1 in humans. The heterogeneity of MDSC in patients with malignant disease has made characterization of these cells diYcult clinically due to the lack of a singular marker. Multiple reports including several reviews have been published that established a clear link between CD15
+ MDSC in cancer patients and Gr-1 + MDSC in mice [1, [8] [9] [10] [11] . Recent studies demonstrate that induction of various subpopulation of MDSC is directly related to the speciWc cytokine proWle of the inducing tumor [29] . Numerous subpopulations have been described in various tumors and include CD15 + CD11b + , CD33 + CD11b + , and CD14 + CD11b + , as well as others [6, 12, 20, [30] [31] [32] [33] [34] . In the course of our prior studies, we observed that human pancreatic adenocarcinoma avidly recruits CD11b + CD15 + myeloid cells to the primary tumor.
Pancreatic adenocarcinoma, henceforth called pancreatic cancer, is a treatment refractory malignancy that represents the fourth leading cause of cancer death in the United States [35] . We have previously observed that pancreatic cancer creates a highly immunosuppressive tumor microenvironment though the production of inhibitory cytokines and the recruitment of immunosuppressive cells [33, [36] [37] [38] , including T regulatory cells. While several reports have implicated MDSC in growth of pancreatic cancer in mouse models [39, 40] , few reports have suggested that MDSC play an important role in patients with pancreatic adenocarcinoma [7] .
Treatments targeting MDSC have demonstrated impaired tumor growth, increased survival, and improved response to vaccine therapies in murine models of breast cancer, glioma, and melanoma [41] [42] [43] [44] [45] . Zoledronic acid, a potent aminobisphosphonate and osteoclast inhibitor initially developed to treat osteoporotic bone disease, has demonstrated eYcacy as an anticancer agent used to treat bony metastasis and prolong disease-free survival in patients with breast cancer [46, 47] . The anti-neoplastic mechanism of zoledronic acid remains poorly understood. Direct apoptotic eVects have been reported [48, 49] as well as indirect mechanisms including inhibition of neoangiogenesis [50] [51] [52] , modulation of T-cell immune response [53] , and prevention of myeloid cell diVerentiation into MDSC [45, 54] .
Few studies have targeted MDSC in pancreatic cancer [55] . In this study, we demonstrate that MDSC represent a clinically relevant immunosuppressive cell subset in human pancreatic cancer and that targeting MDSC in a murine model of pancreatic cancer using zoledronic acid reduces MDSC prevalence and tumor growth.
Materials and methods

ImmunoXuorescence
ParaYn-embedded tissue sections of archived human pancreatic ductal adenocarcinoma were used for immunoXuorescence following standard procedures. Confocal images were scanned at 400X with an axiovert 100 M microscope equipped with a LSM 510 confocal system and software (Zeiss). For co-localization of CD15, Foxp3, Arginase-1, and CD11b, rat anti-human Foxp3 (eBioscience, 10ug/ml), goat anti-human CD11b (Abcam, Cambridge, MA, 1:150), rabbit anti-human arginase 1 (Sigma), and polyclonal mouse anti-human CD15 (Abcam, Cambridge, MA, 1:50) were used, visualized respectively with AlexaXuor 488 Donkey anti-rat, AlexaXuor 555 Donkey anti-goat, AlexaXuor 488 goat anti-rabbit and AlexaXuor 647 donkey anti-rabbit secondary antibodies diluted 1:200 (Invitrogen, Carlsbad, CA).
Flow cytometric analysis of human blood, bone marrow, and tumor in patients with pancreatic adenocarcinoma Informed consent was prospectively obtained from all patients prior to obtaining human tissue or blood according to the institutionally approved Human Studies Committee Protocol. Peripheral blood samples were collected in vacuum tubes containing EDTA (BD Biosciences; San Jose, CA) and processed immediately. Cell surface staining was performed on whole blood (100 l aliquots) and PBMC isolated by Ficoll-density centrifugation using monoclonal antibodies for CD15 (BD Biosciences), CD33 (BioLegend; San Diego, CA), and CD11b (BD Biosciences) according to the manufacturer's instructions. For whole blood samples, red cells were lysed prior to the analysis.
Bone marrow aspirates were obtained from the iliac wing and transferred to vacuum tubes containing EDTA (BD Biosciences). Cells were isolated by Ficoll-density centrifugation and frozen in DMSO with 10% FBS. Cells were then thawed using CTL wash (Cellular Technology Ltd, Shaker Heights, OH), washed and stained with CD45, CD11b, CD15, and CD33 (BioLegend). Analysis was immediately performed.
Samples of fresh human pancreatic tumor tissue were obtained from patients immediately after tumor extirpation and placed into cold RPMI. Tumor tissue was minced into 2-3 mm size pieces, mechanically dissociated using the Miltenyi GentleMACS tissue dissociator, and digested in a buVer containing 1 mg/ml collagenase, 2.5 U/ml hyaluronidase and 0.1 mg/ml DNase for 15 min. The cell suspension was then separated from tissue debris by serial Wltration (70, 40 m cell strainer). Cell surface staining was performed using monoclonal antibodies for CD15, CD45, CD33, and CD11b (BioLegend) according to the manufacturer's instructions after treatment with Fc-block. Corresponding isotope controls yielded no signiWcant staining. All results are expressed as a percentage of CD45 + cells.
Mice and tumor cell line C57BL/6 and OT-1 mice were purchased from Jackson Laboratories (Bar Harbor, ME). Animals were housed in a speciWc pathogen-free animal facility at Washington University and were used according to protocols approved by the Institutional Animal Care and Use Committee. The murine pancreatic adenocarcinoma cell line Pan02 is a nonmetastatic tumor line, syngeneic to C57BL/6 [56] , and was obtained from the DCT Tumor Repository (NCI-Frederick Cancer Research and Development Center, Bethesda, MD).
Mouse model of pancreatic cancer
Six-week-old C57BL/6 mice were injected subcutaneously on the right hind leg with 0.1 x 10 6 Pan02 cells, as previously described [37] . Treatment with zoledronic acid (Novartis Pharma) (30 g/kg/100 l subcutaneously thrice weekly) or placebo (normal saline) was initiated 10 days after inoculation when the tumor became palpable. Tumor volume was determined by caliper measurement and recorded weekly. Animals were followed until death or until any single tumor measured greater than 2 cm. Survival was recorded. All animal experiments were performed in triplicate and compared a minimum of 10 mice in each arm (placebo versus treatment).
Tumor immune cell inWltrate was analyzed at multiple time points after inoculation. Bone marrow was Xushed from non-tumor-bearing Wbulae and femurs. Spleens and tumors were resected, and processed into single cell suspensions. Tumor tissue was minced into 2-3 mm size pieces, mechanically dissociated using the Miltenyi Gentle-MACS tissue dissociator, and digested in a buVer containing 1 mg/ml collagenase, 2.5 U/ml hyaluronidase and 0.1 mg/ml DNase for 15 min. The cell suspension was then separated from tissue debris by serial Wltration (70, 40 m cell strainer). In vivo suppression assay Gr-1 + CD11b + MDSC were isolated from mature Pan02 tumors (diameter > 1 cm) using Xuorescence-activated cell sorting. Purity of MDSC was >99%, conWrmed by Xow cytometry. Six-week-old C57BL/6 mice were inoculated with Pan02, MDSC, or a 1:1 combination of Pan02 and MDSC (10 mice per experimental arm). Caliper measurement was used to calculate tumor volume.
In vitro suppression assays CFSE was purchased from Invitrogen (Carlsbad, CA). 100,000 CFSE-labeled splenocytes obtained from OT-1 mice were co-cultured in 96-well plates with 1 m SIINFEKL peptide and varying concentrations of Gr-1 + CD11b + MDSC isolated from mature tumors, spleen, or bone marrow after successful CD11b + magnetic bead separation (Miltenyi Biotech), according to the manufacturer's instructions. Purity was conWrmed to be >97% by Xow cytometry. After 72 h, cells were subsequently harvested and the CD8 + TcR + cell fraction was analyzed by Xow cytometry for CFSE dilution.
Analysis of tumor cytokine concentrations using the BioPlex assay Mature tumors from zoledronic acid treated and control mice were harvested, Xash frozen using liquid nitrogen, and homogenized in a PBS solution containing a protease inhibitor cocktail (Roche Laboratories, Boulder, CO). Supernatant was reserved after centrifugation (10,000 RPM for 5 min at 4°C) and analyzed for IFN-, IL-2, and IL-10 according to the manufacturer's directions (BioPlex, BioRad Laboratories, Hercules, CA). The cytokine panel was analyzed using the Luminex 100 (Luminex, Inc., Austin, TX) plate reader and data processed using the accompanying proprietary software. Cytokine concentrations were normalized according to the mass of tumor homogenized.
Statistical analysis
Data were analyzed using Graph Pad Prism version 5.01 (GraphPad Software Inc., La Jolla, CA). Survival diVerences between treatment and control groups were compared using Kaplan-Meier analysis, and diVerences were calculated using the log-rank test. Comparison of diVerence between groups was calculated using Student's t-test with P < 0.05 considered to be statistically signiWcant.
Results
Patients with pancreatic adenocarcinoma have increased numbers of CD11b + CD15 + myeloid cells in the bone marrow and the peripheral blood which are avidly recruited to the primary tumor Peripheral blood, PBMC, and bone marrow aspirates were collected from patients with pancreatic adenocarcinoma and cancer-free controls. Human samples were analyzed for the frequency of known markers of MDSC including CD33, CD15 and CD11b. Patients with pancreatic cancer had a signiWcant increase in circulating CD11b + CD15 + myeloid cells both in whole blood samples ( Fig. 1a ; controls n = 5, patients n = 20) and isolated PBMC when compared to controls ( Fig. 1b ; controls n = 12, patients n = 16, P < 0.0001). Myeloid cell mobilization was most notable in patients with metastatic disease (n = 11; 68.2% § 3.6% of CD45 + cells), when compared to both normal controls (n = 10; 37.6% § 3.6%; P < 0.0001) and patients with resectable pancreatic cancer (n = 9; 57.3% § 3.5%; P < 0.05). A similar expansion of myeloid cells was observed in the bone marrow of pancreatic cancer patients (47.7 § 3.9% of CD45 + cells, n = 8) compared to controls (22.3 § 1.4%, P < 0.001, n = 16; Fig. 1c) . A representative Xow cytometric analysis is depicted in Fig. 1c .
Normal human pancreas was devoid of inWltrating CD15 and CD11b expressing cells by immunoXuorescent analysis + CD15 + myeloid cells are upregulated in the peripheral blood and bone marrow of patients with pancreatic cancers when compared to normal controls. Multicolor Xow cytometric analysis of peripheral blood samples of patients with conWrmed pancreatic cancer was obtained prior to surgery. Patients with pancreatic cancer (n = 16) had a signiWcant increase in the prevalence of CD11b + CD15 + PBMC compared to cancer-free controls (n = 12) (***P < 0.0001). Those patients with unresectable, metastatic disease (n = 11) had the greatest burden of CD11b + CD15 + in whole blood compared to those with resectable disease (n = 9) or controls (n = 10) (b *P < 0.01; **P < 0.05; ***P < 0.0001). Analysis of bone marrow cells from patients with pancreatic adenocarcinoma (n = 16) also revealed increased populations of CD11b + CD15
+ compared to cancer-free controls (n = 8; c *P < 0.01). A representative Xow cytometric analysis from PBMC is shown (d) 2a) . In contrast, pancreatic cancers avidly recruited cells that coexpressed CD15 and CD11b (Fig. 2b) , which also coexpressed Arginase-1 (Fig. 2c) . Flow cytometric analysis of human pancreatic tumors allowed further phenotypic discrimination of inWltrating leukocytes (Fig. 2c, d ). The stroma of human pancreatic cancers was noted to have a dense CD45 + inWltrate which was predominantly composed of CD15 + CD11b
+ myeloid cells (66.6% § 3.2%); these cells also coexpressed CD33. By comparison, the percentage of tumor-inWltrating CD4 and CD8 T cells was considerably smaller (16.7 § 2.1 and 9.5 § 1.6%, respectively).
Pan02 inoculated into C57BL/6 mice induces the mobilization of immunosuppressive MDSC and their recruitment to the primary tumor To further study tumor-induced recruitment of MDSC, we used the non-metastatic murine pancreatic adenocarcinoma cell line, Pan02 (aka Panc02) [56] . After inoculation with Pan02, a progressive increase in prevalence of CD11b + Gr-1 + myeloid cells was observed in the spleen (7.8% vs.
18.8% at 30 days; P < 0.01) which was associated with decreased percentages of circulating CD4 (17.6% vs. 8.1%; P < 0.01) and CD8 (13.7% vs. 6.9%; P < 0.01) T cells, and an increased percentage of Foxp3 + Treg (Fig. 3a) . Mobilization and accumulation of CD11b + Gr-1 + cells in the bone marrow, spleen, and primary tumor microenvironment reliably occurred (Fig. 3b) . Flow cytometric analysis of the Pan02 tumors demonstrated that the murine tumor microenvironment closely recapitulates that of human pancreatic cancer. Just as in human tumors, the majority of inWltrating CD45 + leukocytes in Pan02 tumors was comprised of myeloid cells (human: 68%, Pan02: 78%). Conversely, the percentage of immune eVector cells was minimal.
The suppressive potential of the CD11b + Gr-1 + cells isolated from various compartments (bone marrow, spleen, and tumor) was tested using the assessment of CSFE dilution in OT-1 splenocytes stimulated with SIINFEKL peptide + or CD11b + cells as determined by immunohistochemistry; however, patients with pancreas adenocarcinoma were noted to have a dense immune inWltrate composed primarily of cells which coexpressed CD15 and CD11b (b CD11b blue, CD15 red, CD15 and CD11b coexpression magenta). Treg (Foxp3) were noted at a much lower prevalence (green). These cells were also found to highly coexpress 
Treatment with zoledronic acid results in smaller tumors and improved survival
Mice were inoculated with Pan02 and zoledronic acid treatment was administered thrice weekly by subcutaneous injections. There were no adverse side eVects noted in nontumor-bearing mice treated with zoledronic acid (data not shown). Mice treated with zoledronic acid demonstrated signiWcantly delayed tumor growth rate and smaller tumors when compared to animals treated with placebo (P < 0.0001; Fig. 5a ). Importantly, treatment resulted in prolonged median survival (zoledronic acid: 73 days, placebo: 59 days, P = 0.02; Fig. 5b ).
Zoledronic acid impairs the production and recruitment of MDSCs into the periphery, as well as into the tumor microenvironment resulting in an immune-activated host tumor microenvironment
The antitumor eVect of zoledronic acid occurred rapidly with evidence of response after 6 doses. Treatment with zoledronic acid resulted in a statistically signiWcant decrease in intratumoral CD11b + Gr-1 + cells (78% in placebo vs. 51% in zoledronic acid at Day 34, P < 0.05; Fig. 6a) . Additionally, the composition of the tumor immune inWltrate was altered by treatment with zoledronic acid (Fig. 6a-c) , with increases in CD4 + (CD4: 4.4% § 1.1% vs. 12.2% § 2.0%, P = 0.02) and CD8 + T-cell tumor inWltrate (3.9% § 1.3% vs. 10.6% § 2.2%, P = 0.04), and a decrease in the percentage of CD4 cells expressing Foxp3 (Foxp3 as %CD4: 42.2% § 5.0% vs. 22.3% § 6.5%, P = 0.02).
The functional consequence of altering the immune cell balance within the tumor microenvironment was investigated by comparing the cytokine proWles of zoledronic acid-treated Pan02 tumors with placebo-treated controls (Fig. 7) . Various cytokine levels (IFN-, GM-CSF, and IL-10) were measured in homogenates created from fresh, mature tumors. Tumor-bearing mice exhibited an immunosuppressive cytokine phenotype as evidenced by elevated levels of IL-10 and lower concentrations of IFN-. Treatment with zoledronic acid functionally altered the tumor microenvironment toward an immunostimulatory phenotype with statistically signiWcant increased levels of IFN-(P < 0.05) and decreased levels of IL-10 (P < 0.05). Despite a signiWcant alteration in the cytokine proWles between zoledronic acid-treated animals and placebo controls, no diVerence was observed in tumor concentrations of GM-CSF (P > 0.05).
Discussion
Pancreatic cancer remains one of the most aggressive malignancies, with a mortality rate that approaches its incidence [35] . Despite many innovative treatments, including immunomodulatory therapies, pancreatic cancer remains highly resistant to treatment [57] [58] [59] . One manner in which pancreatic cancer evades therapeutic response is by the induction of an immunosuppressive microenvironment. We, and others, have previously described the role of Treg in pancreatic cancer as an eYcient means of preventing adequate host antitumor responses [36, 37, 60] . Recently, myeloid-derived suppressor cells (MDSC) have been accepted as important mediators in tumor-induced immunosuppression.
MDSC are now recognized as a key immunosuppressive cell type in the development and progression of malignancy [33] . The prevalence of these cells and their immunosuppressive capacity has been reported in multiple diVerent malignancies including head and neck, prostate, renal cell, and breast [4] [5] [6] [7] [8] [9] ; however, relatively little research about these cells has been carried out in pancreatic cancer. In this publication, we quantify the frequency of MDSC in human pancreatic cancer, and investigate the role of MDSC depletion in a mouse model of pancreatic adenocarcinoma as a therapeutic modality.
Early research by Schmielau and Finn suggested an increased number of "low density granulocytes" present in patients with pancreatic cancer that possessed an immunosuppressive phenotype [7] . This study focused exclusively on patients with metastatic disease and demonstrated that circulating CD15 + cells isolated from peripheral blood were able to block T-cell function. Although this study laid essential groundwork for the study of MDSC in human cancer patients, it did not thoroughly characterize the cells of interest. We have expanded on this research and demonstrated that the CD15 + cells previously observed represent CD15 + CD11b + MDSC. Other authors have demonstrated a similar increase in granulocytic MDSC in human cancers including bladder cancer, renal cell cancer, colon cancer, and lung cancer [6, 12, 20, 30] . In the current study, we demonstrate that CD15 + CD11b
+ cells are not only upregulated in the peripheral blood of patients with pancreatic cancer, but they are also observed in increased prevalence in the bone marrow; most importantly, these cells inWltrated tumors in large numbers. In addition, increasing prevalence of the CD11b + CD15
+ cells in peripheral blood correlates with more advanced disease state. Patients with biopsy proven pancreatic adenocarcinoma have increased numbers of phenotypic MDSC when compared to normal, agematched controls, and patients with metastatic disease had signiWcantly increased numbers over patients with local disease (Fig. 1) . In addition, these cells were found to coexpress Arginase-1, a key method of MDSC immunosuppression that has repeatedly been demonstrated throughout the literature [6, 12, 20, 30, 33, 76] . These Wndings are similar to other studies, which correlate MDSC prevalence with clinical disease stage in patients with advanced cancer including pancreatic cancer [10] .
Through soluble mediators, the primary tumor has been implicated in the generation of MDSC in the bone marrow, mobilization into the peripheral circulation, homing to the primary tumor, and imprinting of the immunosuppressive phenotype [2, 3, 27, 29, 32, 45] . This is the Wrst publication demonstrating increased numbers of MDSC in the bone marrow of patients with solid tumors. Numerous factors are associated with the mobilization of these cells from the bone marrow including IL-6, IL-10, GM-CSF, G-CSF, SCF, and CCL2 [2, 27, 29, 32, 42, [61] [62] [63] [64] [65] [66] . The variation in MDSC phenotype between diVerent cancer types is likely related to diVerential production of chemokines by the primary tumor that results in a heterogeneous myeloid cell population [29, 32, 67] .
The above-mentioned heterogeneity has made the study of these cells diYcult in human patient populations. We observed that human pancreatic cancer tumors avidly recruit CD15 + CD33 + CD11b + MDSC into the peripheral circulation and to the primary tumor. In human pancreatic adenocarcinoma, these cells represent the majority of tumor-inWltrating leukocytes and greatly outnumber tumorinWltrating lymphocytes, including Treg (Fig. 2) . We recently observed that a subset of CD11b + cells with a monocytic phenotype (CD14 + CD33 + ) also inWltrate human pancreatic cancers, and ongoing eVorts focus on functional and phenotypic characterization of this subset, as monocytic MDSC have been described in a variety of human cancers as well as animal models [33] .
Interestingly, comparison of the circulating MDSC to those found within the tumor microenvironment demonstrates notable diVerences in cell surface marker phenotype. CD15 expression was variable between tumor-associated and circulating MDSC. In addition, CD33 expression on tumor-derived MDSC segregated into two populations: CD33 hi and CD33 lo . Although phenotypic analyses were unable to be carried out on the MDSC subgroups because of small quantities of human specimen, it can be postulated that the diVerential expression of cell surface markers was the result of imprinting on the MDSC mobilized from the bone marrow by tumor-derived factors. Recently, Rodrigues et al. [68] described that monocytes from normal donors exposed to malignant glioma cells adopted an immunosuppressive phenotype and exhibited increased CD33 expression. Importantly, it was also noted that direct cell contact was necessary to "educate" normal donor monocytes to develop maximal immunosuppressive phenotype, a Wnding that is supported by our data as we observed maximal suppression induced in tumor-conWned MDSC. Additionally, a recent published report suggests that peripheral MDSC are skewed toward suppressive function but require activation in the tumor microenvironment to develop full suppressive potential [69] , also supported by our data. Variable "imprinting" or "education" of MDSC was observed in our Pan02 mouse model of pancreatic cancer. In tumor-bearing mice, Gr-1 + CD11b + cells were isolated from various compartments and their individual suppressive potential was measured on T-cell proliferation, with tumor-associated MDSC having the highest suppressive potential. Although all MDSC shared the same cell surface markers, their ability to suppress antigen-mediated T-cell response varied. MDSC isolated from the bone marrow were essentially inert; splenocyte-derived MDSC were immunosuppressive but by a much smaller degree than MDSC isolated from tumor. The immunosuppressive variability suggests that MDSC mobilization from the bone marrow and the development of the immunosuppressive phenotype may be isolated processes, separated both temporally and anatomically. Current cell surface markers used to identify MDSC in both animal models and humans are not suYcient given the phenotypic and functional variability of these heterogeneous cells. This is especially true in humans where cell surface markers are less speciWc than in murine model and the actual MDSC cell population is likely a subset of CD15 + CD11b + cells. Given the abundance of MDSC in the primary tumor and circulation of patients with pancreatic cancer, we hypothesized that these cells play an instrumental role in the engraftment and support of the primary tumor. We selectively targeted MDSC using zoledronic acid, a potent and bone avid aminobisphosphonate that has previously been shown to target MDSC in breast and cervical cancer [44, 45, 70] .
In mice inoculated with Pan02, zoledronic acid eVectively decreased the rate of accumulation of MDSC in the tumor microenvironment resulting in impaired tumor growth and prolonged survival; however, the exact mechanism of impaired MDSC accumulation by zoledronic acid is unclear [44, 48-52, 70, 71] . Regardless of the mechanism, zoledronic acid eVectively decreased accumulation of MDSC to the tumor and phenotypically altered the tumor microenvironment. This allowed for the host to mount a more robust T-cell response, as evidenced by a shift in the cytokine proWle from immunosuppressive to immunostimulatory and increased prevalence of eVector CD4 and CD8 T cells. The resulting decreased tumor growth and improved survival suggests that MDSC play an important role in the progression of pancreatic cancer.
It is possible that zoledronic acid has a direct eVect on the primary tumor, as in vitro studies have shown antitumor activity [48, 49] . However, bioavailability studies looking at soft tissue and bone concentrations of zoledronic acid demonstrate that even with supratherapeutic daily dosing greater than used in this study (150 g/kg/day), zoledronic acid did not accumulate at clinically appreciable levels in the pancreas or soft tissues [72] . Concentrations of zoledronic acid detected in bony tissues were up to 1,500-fold greater than the non-mineralized tissues and at least 4,000-fold higher than in plasma [72] . Therefore, it is unlikely that zoledronic acid would have direct anti-tumor eVects in vivo [48, 49] .
Although we observed a signiWcant reduction in rate of tumor growth and an improvement in survival in mice treated with zoledronic acid, all animals eventually died from progressive disease. There are several possible reasons why zoledronic acid was not able to cure mice inoculated with Pan02. First, tumors promote immunosuppression and immune evasion through multiple redundant mechanisms, including Treg. Zhang et al. [73] elegantly demonstrated that although elimination of these cells is suYcient to abrogate tumor growth, it is unable to eVect complete tumor eradication. This suggests that local tumorinduced immunosuppression is multifactorial, and single arm therapies are unlikely to be suYcient. Second, Treg also play an important role in immune invasion in pancreatic cancer [36, 37, 60, 74] . Treatment with zoledronic acid resulted in a decreased percentage of CD4 + Foxp3 + cells. While the concomitant increase in tumor-associated CD4 T cells resulted in an unchanged absolute number of Treg, the increased prevalence of CD4+ Foxp3
¡ cells altered the ratio of immune eVectors to immune suppressors in favor of immune eVectors. However, the continued presence of Treg likely plays an important role in immune evasion in the setting of decreased MDSC.
Our above data indicate that MDSC are an important immunosuppressive cell active in the immune evasion elicited by pancreatic adenocarcinoma and that the depletion of these cells may provide a novel therapeutic modality for the treatment of this aggressive malignancy. Zoledronic acid is eVective in depleting tumor-associated MDSC; however, its mechanism of action is unknown and leaves room for improvement, as all mice in our studies eventually progressed to death from disease. Combination therapy with chemotherapeutic modalities may provide improved outcomes [75] . In this vein, we are currently conducting a clinical trial to investigate the immune eVects and clinical eYcacy of zoledronic acid in patients with resectable pancreatic cancer (ClinicalTrials.gov identiWer: NCT00892242). Information gained from such trials will be useful to dissect the complex immunologic role of MDSC and therapeutic beneWt of MDSC targeting strategies. Novel therapeutic modalities targeting tumor-induced immunosuppression with immunostimulatory treatments and chemotherapy are urgently needed to overcome this aggressive malignancy.
